Compare BioNTech SE - ADR (BNTX) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs JPMorgan Chase & Co — how do they compare? BioNTech SE - ADR trades at $89.8 (market cap $22.86B), while JPMorgan Chase & Co trades at $349.12 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 39.9× BioNTech SE - ADR's market cap, and JPMorgan Chase & Co pays a 1.75% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | JPM | |
|---|---|---|
Market Cap | $22.86B | $911.47B |
Sector | Health | Financials |
52-Week High | $119.34 | $342.89 |
52-Week Low | $83.89 | $282.84 |
Enterprise Value | $6.53B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
JPMorgan Chase (JPM) trades at $345.02, up 3.14% with strong technical momentum. The stock shows robust fundamentals with $181.85B revenue and $57.05B net income for 2025, supported by a 17.03% ROE. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus remains bullish with a $377.75 price target. Technical indicators signal bullish momentum with support at $333 and resistance at $336.
JPM offers solid upside potential driven by earnings momentum and strong profitability, though risks include geopolitical tensions and cybersecurity threats highlighted in recent news. The stock's valuation at 14.69 P/E appears reasonable relative to peers, supporting a moderate buy outlook with caution on macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
